Clinical Evaluation of Grandaxin^® (Tofisopam) on several skin diseases

Abstract

The efficacy, safety and usefulness of tofisopam (Grandaxin^®), an automatic regulating drug, were examined on several skin diseases by open trial. Grandaxin was administered in 53 patients, of whom 14 had pruritus cutaneus universalis, 7 pruritus cutaneus localis, 16 chronic urticaria, 11 hyperidrosis and 5 dyshidrotic eczema. The result rated as useful was seen in 36% of pruritus cutaneus universalis, 71% of pruritus cutaneus localis, 31% of chronic urticaria, 45% of hyperidrosis and 40% of dyshidrotic eczema.
Mild side effects were seen in 2 cases (3.8%). One was staggering, and other was nausea and diarrhea, but these symptom promptly disappeared by cessation of the drug. These results indicate that tofisopam (Grandaxin^®) is a useful drug for these intractable skin diseases.